Dr. Anne S. Tsao

Doctor Overview

As director of the mesothelioma program at the MD Anderson Cancer Center at the University of Texas in Houston, Anne Tsao MD is one of the nation’s foremost authorities on malignant mesothelioma.

Dr. Tsao and her colleagues at Anderson have penned many articles providing a large amount of information for many professional journals and have been involved in numerous clinical trials involving the treatment of malignant mesothelioma, an aggressive form of cancer that is often diagnosed in advanced stages and difficult to treat.

In articles in publications such as the Journal of Clinical Oncology, Tsao has discussed the impact of novel therapies, the importance of clinical trials, and controversial issues such as the use of extrapleural pneumonectomy in the treatment of the disease. She has also campaigned for the use of intrapleural therapies as well as gene therapy and immunotherapy for the treatment of malignant pleural mesothelioma and lectures nationally and internationally on these subjects.

Tsao has also performed studies involving smoking history and its impact on the prognosis of those with non-small cell lung cancers like mesothelioma. She has also stressed the need for chemo-prevention, the use of natural, synthetic, or biologic chemical agents to suppress cancer in high-risk populations or prevent carcinogenic progression to invasive cancer.

Doctor Fast Facts

Main Specialty: Thoracic Medical Oncology

Other Interests & Specialties: Individualized cancer therapy, mesothelioma and lung cancer.

Certifications, Awards & Accolades: Co-Chair of the MDACC Clinical Research Committee, Scientific Advisory Committee member, chairing session participant for American Radium Society, Chair of the Communications Committee for International Association for the Study of Lung Cancer (IASLC), Chair of the Mesothelioma Applied Research Foundation (MARF), SWOG Executive Lung Committee member, SWOG Mesothelioma Steering Committee member, DSMB for NRG Thoracic Oncology member, NRG Lung Executive Committee member

Education & Experience:

• Internship and Residency at Indiana University
• Medical Oncology Fellowship at the University of Texas MDACC
• Medical Degree from the University of Chicago Pritzker School of Medicine

Did You Know? There are approximately 3,000 mesothelioma cases per year in the U.S. Many doctors have little or no experience with this rare cancer. It is imperative to consult with an experienced mesothelioma specialist to ensure you or a loved one receives the best treatment plan possible. Connect With a Top Mesothelioma Doctor

Publications

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. September 2016. doi: 10.1200/JCO.2005.02.477

Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). BioMed Central Ltd. in Head & Neck Oncology. June 2010;2(1):15. doi: 10.1186/1758-3284-2-1-15

Mesothelioma Clinical Trials by Anne S. Tsao, MD

Dr. Tsao is associated with the following clinical trials: